Press Release February 21, 2007

Locus Pharmaceuticals Raises $30.2 Million in Series B-1 Financing

Feb. 13, 2007 — Locus Pharmaceuticals Inc., a computationally based drug design and development company, announced today that it has closed on a $30.2 million financing. Novartis Bioventures Ltd., Prism Venture Partners and HBM BioVentures (Cayman) Ltd. co-led the round. S.R. One Limited and L Capital Partners SBIC L.P. also participated, as did certain other existing shareholders of the Company.

Locus Pharmaceuticals is focused on developing novel, small molecule therapeutic drugs to address major unmet medical needs. It has effectively integrated its core technology with the application of chemistry and biology expertise to advance three internal programs that address new therapeutic modalities for the treatment of HIV/AIDS, cancer and arthritis/inflammation.

Goodwin Procter attorneys Laurie Burlingame, Kingsley Taft and William Walt represented Prism Venture Partners in this transaction.